Oncology Central

Immunotherapy for ovarian cancer: what are the targets of the future?


Ovarian Cancer

Epithelial ovarian cancer affects approximately one in 70 women and is characterized by presentation at late stages resulting in poor survival outcomes, with only 45% of women surviving 5 years after diagnosis [1]. Standard treatment of ovarian cancer includes surgery and cytotoxic chemotherapy. Unfortunately, although up to 80% of women achieve clinical remission with this regimen, the majority will experience relapsed disease, the development of chemotherapy resistance, and death due to cancer-associated morbidity [2].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.